Elo Mutual Pension Insurance Co Buys 1,417 Shares of Amgen Inc. $AMGN

Elo Mutual Pension Insurance Co increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,898 shares of the medical research company’s stock after acquiring an additional 1,417 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Amgen were worth $17,750,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Cobblestone Capital Advisors LLC NY raised its position in Amgen by 2.1% during the 3rd quarter. Cobblestone Capital Advisors LLC NY now owns 1,731 shares of the medical research company’s stock valued at $488,000 after purchasing an additional 35 shares during the last quarter. Fisher Asset Management LLC increased its stake in shares of Amgen by 91.6% during the third quarter. Fisher Asset Management LLC now owns 785,284 shares of the medical research company’s stock valued at $221,607,000 after buying an additional 375,463 shares during the period. New Age Alpha Advisors LLC raised its holdings in shares of Amgen by 3.0% during the third quarter. New Age Alpha Advisors LLC now owns 41,651 shares of the medical research company’s stock valued at $11,754,000 after acquiring an additional 1,211 shares in the last quarter. Holderness Investments Co. lifted its stake in Amgen by 2.2% in the third quarter. Holderness Investments Co. now owns 7,786 shares of the medical research company’s stock worth $2,197,000 after acquiring an additional 169 shares during the period. Finally, Patrick M Sweeney & Associates Inc. boosted its holdings in Amgen by 6.4% in the third quarter. Patrick M Sweeney & Associates Inc. now owns 1,037 shares of the medical research company’s stock valued at $293,000 after acquiring an additional 62 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on AMGN shares. Daiwa Securities Group raised their target price on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Leerink Partners lifted their price target on Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. Cantor Fitzgerald boosted their target price on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Freedom Capital cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 12th. Finally, Rothschild & Co Redburn lifted their target price on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and an average price target of $351.76.

Amgen Price Performance

NASDAQ:AMGN opened at $388.16 on Monday. The business’s 50-day moving average is $348.89 and its 200 day moving average is $319.93. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $390.14. The company has a market capitalization of $209.24 billion, a P/E ratio of 27.28, a P/E/G ratio of 3.85 and a beta of 0.46. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 2.6%. Amgen’s dividend payout ratio is 70.84%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported a new evolocumab bioavailability study that refines dosing/PK assessment for its PCSK9 cholesterol franchise, signaling management’s continued investment in a long‑lived cardiovascular product line and potential lifecycle optimization. Amgen Fine-Tunes Evolocumab
• Positive Sentiment: Amgen advanced maridebart (cafraglutide) toward a Phase 2b obesity and liver‑fat trial — news that expands the company’s obesity pipeline and supports upside potential beyond core biologics. Pipeline progress tends to lift pharma multiples. Amgen Advances Maridebart
• Positive Sentiment: Coverage and momentum narratives are supportive — Zacks highlights AMGN as a top long‑term momentum stock, which can attract trend‑driven and fund flows. Why Amgen is a Top Momentum Stock
• Positive Sentiment: Market headlines note AMGN reaching an all‑time high and outperforming the Dow recently — reinforcement for bullish sentiment and potential technical buying. Amgen stock hits all-time high Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Biotech sector activity: a large biotech IPO (Generate Biomedicines) indicates healthy capital markets for life sciences, which can be a neutral tailwind for large biotech names but doesn’t directly change Amgen’s fundamentals. Generate caps a strong month for biotech IPOs
• Neutral Sentiment: Minor portfolio rebalancing: a small sale by Bradley Foster & Sargent reduced a modest position in AMGN — not material to shares outstanding or sentiment. Bradley Foster & Sargent sells AMGN
• Negative Sentiment: Policy risk: a proposed U.S. bill to tighten rules on corporate inversions mentions AMGN among companies potentially affected by changes to international tax treatment — could raise longer‑term tax/structural uncertainty if enacted. Impact is uncertain and likely small near term. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported short‑interest data in feeds looks inconsistent (zeros/NaN) and should be treated with caution; no clear signal from short interest trends. (data sources above).

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.